Antibiotics Deals are Blossoming
Executive Summary
Biotech has joined the new war on infectious diseases-for sound business reasons.
You may also be interested in...
Getting the Bugs Out of Antibiotic R&D: Commercial Implications of a Higher Regulatory Hurdle
It's a gloomy time for antibiotic R&D: higher regulatory hurdles and commercial challenges have forced many companies to leave the market. But a few major players and boutique firms remain committed to the field. What do they see that the rest of the industry is overlooking?
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.